Facilitated By

San Antonio Medical Foundation

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AEROVANC FOR THE TREATMENT OF PERSISTENT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS LUNG INFECTION IN CYSTIC FIBROSIS PATIENTS

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Willey-Courand, Donna Beth
Funded by
SAVARA PHARMACEUTICALS INC.
Research Start Date
Status
Active
Collaborative Project
Clinical Care
Drug Discovery
Infectious Disease